Why the study?
Improved life expectancy from cancer treatment advances makes TAVR a potential option, but differences in mortality between cancer and non-cancer patients remained to be evaluated.
Does transcatheter aortic valve replacement (TAVR) in patients with cancer compared to those without cancer result in different short- and long-term all-cause mortality?
Meta-Analysis (n=12,165)
Does transcatheter aortic valve replacement (TAVR) in patients with cancer compared to those without cancer result in different short- and long-term all-cause mortality?
Relative Risk: 1.43 (95% CI 1.26–1.62)
p-value: p=<0.01
TAVR in cancer patients with severe aortic stenosis is associated with similar short-term mortality but higher long-term mortality compared to non-cancer patients, highlighting the need for individualized decision-making based on life expectancy.
No takes yet. Share an insight, caveat, or question.
Siddiqui et al. (2022) conducted a meta-analysis in Severe symptomatic aortic stenosis (n=12,165). Malignancy vs. No malignancy was evaluated on Long-term all-cause mortality (RR 1.43, 95% CI 1.26-1.62, p=<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: